Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Pain drug developer Latigo Biotherapeutics has joined a queue of more than half a dozen other biotechnology startups that announced this month plans to go public. Founded in 2018 by the venture ...

Initial public offerings make the biotechnology industry tick. Stock listings give young companies the funding they need to develop their drugs, and their venture backers an opportunity to earn a ...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.